Iktos announces that Kissei Pharmaceutical Co., Ltd., a Japanese pharmaceutical company with approximately 75 years of history, specialized in the field of urology, kidney-dialysis and unmet medical needs, has introduced Makya™, Iktos Software as a Service Platform for AI-driven drug discovery. This will enable the rapid and efficient design of new small molecules, leading to an increase in the speed of drug discovery and development. Follow the link for the full press release.